#targeted therapy

Recommendations now include multiple systemic medications in addition to surgery and local therapies.

The life-or-death distinction for melanoma patients

Indication extended to include first-line treatment of HR-positive/HER2-negative advanced or metastatic disease.

“Cancer forces you to get in the fight, to choose the things you really want to do—and do them,” Joan Janssen says.

Lynparza is now indicated for breast cancer patients with BRCA mutations.

First FDA-approved treatment for patients with BRCA-mutated HER2-negative metastatic breast cancer.

Talazoparib may offer an additional option for women with BRCA gene mutations.

Venclexta combination therapy clears leukemia in blood and bone marrow, recent studies show.

New study suggests longer hormone therapy may help prevent cancer recurrence.

New treatment approaches target tumors with shared characteristics, regardless of where they appear in the body.

Revlimid improves outcomes for chronic lymphocytic leukemia patients, but better drugs are now available.

FDA approves sunitinib malate (Sutent) for the adjuvant treatment of adults at risk for kidney cancer recurrence.

FDA grants regular approval to obinutuzumab (Gazyva) for adults with previously untreated follicular lymphoma.

Approval was based on a phase 3, randomized, open-label, multicenter clinical trial (ALCANZA).

FDA approves dasatinib (Sprycel) for children with Philadelphia chromosome-positive chronic myeloid leukemia.

FDA grants regular approval to Alecensa for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.